

CEO BOARD UPDATE

Seth Berkley, CEO



CEO Board Update 16 December 2020

1

Key developments: Gavi, the Vaccine Alliance

International recognition

Gavi, the Vaccine Alliance



Princess of Asturias Award for International Cooperation 2020



Government of the Netherlands
2020 scorecard: good (highest category)



2020 Aid Transparency Index score:
very good (highest category)

Gavi Secretariat



Gender EQUAL-SALARY
certification: 3rd consecutive year




Credit: © Fundación Princesa de Asturias @fpa


2

Core programmes: transitioning from Gavi 4.0 to 5.0

Gavi 4.0: more children protected against more vaccine-preventable diseases than ever before










COVID-19 pandemic affected new vaccine introductions, raising risk of outbreaks



COVID-19: impact on routine immunisation services

Promising signs of restoring previous coverage levels on average across countries, but urgent catch-up of missed cohorts remains a priority



Source: Monthly admin estimates, November 2020


Note: Only preliminary data available for July 2020 (20 countries) and August 2020 (16 countries).

Overall, through June 2020, ~15% decline in children vaccinated in 2020 compared to 2019

- 50 countries reporting represent 90% of Gavi68 surviving infant population
- 80% of missed children reside in 5 countries; 10 countries had little or no difference in children vaccinated
- Note: Admin data is subject to biases that may be exacerbated in the COVID-19 environment

COVID-19: overall stabilising trends of UNICEF global vaccine shipments

Number of vaccine shipments delivered by week, 2019–2020



Number of shipments, number of countries reached per week: within pre-pandemic levels

Source: UNICEF Supply Division, December 2020

● 2019 ● 2020

COVID-19: programmatic response

Enduring focus: equitable routine immunisation, resilient health systems

Respond and protect

- Board approved flexible funding to countries: complement national response plans, protect immunisation
- Front-loaded US\$ 40 million to UNICEF SD for COVID-19 commodities (US\$ 30.4 million drawn down)
- Disbursed US\$ 6.4 million to UNICEF for charter flights
- 69 reprogramming requests totalling US\$ 80 million – *infection prevention and control (IPC) measures* = >50% of Gavi support

Maintain, restore and strengthen

- In-country, multi-stakeholder dialogues to review: impact of COVID-19; programmatic adjustments; repurposing Gavi support
- Guidance to countries on use of support
- ~50% of countries indicated intention to reprogramme existing HSS & TCA support

Build back better



Recalibrating Gavi 5.0 priorities

Maintain, restore and strengthen immunisation

- Catching up on children missed before and during pandemic

Reaching “zero-dose” children and missed communities

Supporting timely access to COVID-19 vaccines

Safeguarding domestic financing for immunisation

Strategic pacing, given limited country and Alliance capacity


- New vaccine introductions
- Engagement with middle-income countries (MICs)

Additional priorities in 2021

- Vaccine-preventable disease (VPD) surveillance; innovation; India strategy


Riskier strategy in a riskier world

- Higher risk exposure



Taking action now to prevent measles resurgence

Measles case distribution by month and by WHO region
(January 2016–October 2020)



Ref: Measles Outbreaks Strategic Response Plan: Measles outbreak prevention, preparedness, response and recovery, 2021-2023 (Draft). World Health Organization 2020

Developments in 2020

COVID-19 impact

- Reported measles cases plummeted in Q2 2020 (WHO) due to reduced surveillance capacity and possibly reduced contact rates
- Temporary decrease in MCV1/MCV2 coverage
- 48 million children at risk due to delayed MCV campaigns in 10 Gavi-supported countries

Taking action against growing risk of costly measles outbreaks

- Proactive catch-up vaccinations through routine services
- Resumption of planned campaigns, including integrated activities where programmatically feasible

Looking ahead: polio



African Region certified free of wild poliovirus

On 25 August 2020, after four years without a case

Circulation of vaccine-derived poliovirus causing cases of paralysis; fuels anti-vaccine movement



Global polio priorities: IPV2 & nOPV2

Gavi: Roll-out of second dose of inactivated polio vaccine (IPV2) starting in 2021

GPEI: Preparations under way for nOPV2 roll-out under EUL by January 2021 to sustainably address increasing scope of vaccine-derived outbreaks



New director Aidan O'Leary
starting 1 January 2021

WHA commitment (November 2020):
plea for international solidarity,
following WHO/UNICEF call for
emergency action

Continuing the fight against Ebola virus disease (EVD)



11th EVD outbreak in Democratic Republic of the Congo (DRC) declared over in November

>40,000 people vaccinated as part of outbreak response in Équateur province

No new confirmed cases reported since 28 September



Other developments

SAGE deliberations on vaccination outside outbreak settings for high-priority groups (e.g. health care workers)

Ebola to become fourth disease under International Coordinating Group (ICG) on Vaccine Provision

Procurement under way to constitute Gavi-funded stockpile of licensed vaccine (500,000-dose target)

In late December, stockpile level will reach 14,450 doses of licensed Ebola vaccine

3

COVAX & COVID-19 vaccines


COVAX partners




Civil society representatives

Power of science & political will: expedited timeline for COVID-19 vaccine roll-out

333 days from genome sequence to approved vaccine in the clinic



COVID-19 vaccine landscape: 49 in clinical evaluation








● COVAX MoU or Sol signed
 ● EUA¹ from SRA
 ● CEPI agreement signed
 ○ COVAX R&D candidate
 ○ CEPI funded candidate for R&D outside COVAX R&D portfolio
 — Discontinued

Source: RDMIC Secretariat

Candidates that have not been able to confirm the dosing of the first subject have not been included in this mapping (e.g. Providence, Kentucky, U. Tübingen). 1. Emergency use authorisation (EUA) from a stringent regulatory authority (SRA).

Initial efficacy results from Phase III trials: need for greater transparency of clinical data

					
Technology platform	mRNA	mRNA	Viral vectors	Viral vectors	Inactivated
Preliminary point estimate of vaccine efficacy	95% (p<0.0001)	94.1% (p<0.0001)	70% (p<=0.0001) (pooled) 90% and 62% (LH and HH regimens ¹) (p<=0.0001)	91.4% 28 days post-dose 1 (7 days post-dose 2); statistical significance not reported	86% effective
Phase 3 study enrollment	43,661 participants to date, 41,135 of whom received a second dose of the vaccine	30,000 participants	UK trial: 12,390 subjects, 2,742 with LH (90% efficacy) UK/Brazil trial: 10,300 HH (62% efficacy)	40,000 participants 22,000 vaccinated with dose 1 and >19,000 with dose 2	31,000 participants
Total number of cases	170 cases (8 in vaccine group) 10 severe cases (9 in placebo, 1 in vaccine group)	196 cases (11 in vaccine group) 30 severe cases (inc. 1 death), all in placebo group	131 cases across 2 trials No severe or hospitalised cases in vaccinees	39 cases No information provided on case severity	No cases reported 100% effectiveness in preventing moderate & severe cases of the disease
Cold chain	-80°C, 2–8°C for up to 5 days	-20°C, 2–8°C for up to 30 days	Storage, transport and handled 2–8°C for up to 6 months	2 versions: • Lyo 2–8°C • Liquid Frozen -20°C	2–8°C for up to 30 days
Plans for licensure	U.S. FDA authorisation for EUA, EMA and WHO EUL/PQ, temp authorisation UK MHRA	Rolling submissions: U.S. FDA for EUA, EMA, plan to WHO for EUL/PQ	Rolling submissions: EMA, MHRA, PQ	Emergency authorisation: Russia Timeline for non-Russian submissions under assessment	UAE

1. LH: low dose followed by high dose; HH: 2 doses of high-dose formulation.

The COVAX Facility has 190 confirmed and eligible participants

AMC-Eligible Economies

92 lower-income economies

- 82 vaccine request applications received
- US\$ 2.4 billion mobilised

Self-Financing Participants (SFPs)

69 SFPs


- 30 Committed purchase
- 39 Optional purchase
- Upfront payments of US\$ 1.3 billion and guarantees of US\$ 1.1 billion

+ 29 Team Europe

The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of Gavi concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Lines on the map represent approximate border lines for which there may not yet be full agreement. This map is continually being updated as information is processed.


Some countries are expected to have excess doses available

Excess doses, assuming no attrition




1. 27 member countries of the European Union.

Several steps are key for country readiness for Q1 2021



Building vaccine confidence and demand during a pandemic

“Global attitudes on a COVID-19 vaccine” (Ipsos survey conducted in October)



Source: <https://www.ipsos.com/en/global-attitudes-covid-19-vaccine-october-2020>. Base: 4,859 online adults aged 16–74 across 15 countries who disagree somewhat or strongly that “If a vaccine for COVID-19 were available, I would get it.” *Online samples in Brazil, China, India, Mexico and South Africa tend to be more urban, educated and/or affluent than general population.

1 in 10 respondents against vaccines in general (inc. 14% in India & South Africa)

Two main reasons for not wanting to get a COVID-19 vaccine are concerns about:

- Side effects: 34%
- Clinical trials moving too fast: 33%

Alliance-wide initiatives

- Vaccination Demand Hub ramping up
- Systems to address “infodemic of misinformation”
- COVAX Country Readiness and Delivery workstream

4

Gavi Secretariat update

Gavi Secretariat update

Virtual Secretariat, concrete progress

- Secretariat remote working/collaboration enhanced
- COVID-19 crisis response plan continues
- Duty travel suspended until end March 2021 – *unless exceptionally authorised*
- Organisational review reaching completion
- Justice, Equity, Diversity & Intersectionality (JEDI) – *staff initiative supported by Gavi leadership*

New ways to stay connected, maintain morale

- All-staff newsletter; knowledge-sharing meetings; radio show
- Mental health awareness sessions
- “Chai and Perspectives” discussions guided by ombudsman
- Virtual year-end celebration: OneGavi@Home



Gavi Secretariat update

New senior appointments



Brenda Killen
Director, Governance
July 2020



Ian MacTavish
Director, Finance
Chief Accounting Officer
September 2020



Aurélia Nguyen
Managing Director,
Office of the COVAX Facility
October 2020

Previously Gavi's Managing Director
for Vaccines & Sustainability

5

Board news

Board Alumni Network



First meeting held in November 2020

With incredible gratitude to outgoing Board Chair Dr Ngozi



Welcome to new Board Chair José Manuel Barroso

In September 2020, Gavi Board unanimously approved Barroso as its new Chair

- Former Prime Minister of Portugal and former President of the European Commission
- Chair, Goldman Sachs International
- On 1 January 2021, Barroso will replace Dr Ngozi, whose term ends in December 2020
- Extensive onboarding process for core Gavi work and COVAX



“The world needs Gavi now more than ever, both to ensure COVID-19 vaccines reach every country, rich and poor, and to press ahead with its core mission to protect hundreds of millions of people from preventable diseases.”

— José Manuel Barroso

Thank you

CEO Board Update 16 December 2020

